West Lafayette, Indiana June 26, 2014- Cancer is rarely black and white, and it's no small matter no matter how small, but a new discovery in the field of cancer screenings has come to light that signals a shift to an earlier, more certain and specific cancer diagnosis.
That discovery is called the ENOX2 protein, and now, with its more readily available testing, it just might have the power to shift how we identify cancer for good.
What is ENOX2?
The ENOX2 protein species resides inside the blood and is unique only to malignant cancer cells. These proteins serve as highly sensitive markers for early detection in both primary and recurrent cancer. These findings are based on research documented in Morre' and Morre', ECTO-NOX Proteins, Springer New York, 2013, Print.
Beyond even this discovery, another aspect that makes the ENOX2 protein unique is its ability to identify 27 forms of cancer at their earliest possible development. That means it has the potential to detect cancer before other cancer screening tests on the market today and can also be used as a non-invasive follow-up option to a high PSA, suspicious mammogram, suspicious PET scan, etc.
How do doctors test for the ENOX2 protein?
The test that coincides with the marker of ENOX2 is called the ONCOblot Test. The ONCOblot Test is a simple blood test, using western blot analysis, that takes a blood sample that will then be sent for evaluation at the recently expanded ONCOblot Laboratory to determine presence of the ENOX2 protein.
If the cancer diagnosis is positive, the ONCOblot Test has the ability to indicate what specific organ site the ENOX2 protein was found in, and deliver patients the results that afford them more time, and targeted treatment options.
What this means for the future
The discovery of this ENOX2 protein, and its implications for the future of cancer screening, provide a hopeful outlook for true cancer elimination. With the ENOX2 protein and the ONCOblot Test, new roads are now paved for more minimally invasive tests, reduced time and money, and more options when it comes to battling a disease that shouldn't be given such power over the lives of many.
|Contact: Rebecca Davis|